Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal-bolus insulin in UK clinical practice.

People with type 2 diabetes (T2D) often require complex treatment regimens, including insulin, to achieve glycaemic goals.1 A basal–bolus insulin regimen combines basal insulin injections (at morning and/or night) and mealtime insulin injections. Although this is effective,2 it can prove burdensome,3 which may be a particular concern in older people. It is important to evaluate simplified regimens that may provide outcomes that are as effective as those achieved with a basal–bolus regimen while reducing treatment burden.4

Biphasic insulin aspart 30/70 (BIAsp 30) is a premixed combination of rapid-acting and intermediate-acting insulin aspart, administered via prefilled pen.5 This combination requires fewer pens and injections (typically 2–3 injections daily) compared with a basal–bolus regimen (usually ≥4 injections daily). However, real-world evidence of the effect of adding BIAsp 30 to a patient's treatment regimen is limited.6 We aimed to address this gap by evaluating glycaemic levels in people with T2D after adding or switching to treatment with BIAsp 30 in real-world clinical practice.